“Excellent speakers, very interesting, thoroughly evidence-based and engaging” Previous delegate
Learning outcomes and key takeaways
- Consider whether therapeutic intervention for ADHD depends on scientific progress
- Understand the role of genetic and environmental factors in the aetiology of ADHD, and the implications for treatment
- Recognise that ADHD is a neuro-biologically heterogeneous condition, and ask whether it is important to tailor treatments to address different causal profiles in different individuals
- To be aware of, and critically appraise, available evidence synthesis on the pharmacological and non-pharmacological treatments for ADHD
- To appreciate to which extent current guidelines are based on empirical evidence
About the day
Neuroscience provides a rational basis for the discovery of new and/or more effective treatments for ADHD. Over the last twenty years our view of ADHD neurobiology has changed considerably, with modern views emphasising its complexity and heterogeneity. This provides a potential platform for personalised therapeutic approaches. Our increasing appreciation of the plastic nature of the brain during sensitive developmental windows highlights the potential value of psychological treatments delivered early in development. There is no evidence, from blind raters, suggesting that non-pharmacological strategies for ADHD are efficacious for ADHD core symptoms. The effect sizes for ADHD drugs from short term trials are amongst the highest not only in psychiatry, but also in general medicine. Network meta-analyses aimed to rank ADHD treatments according to their efficacy/safety have been published or are being conducted.
“Excellent Masterclass! Very informative with clear practical tips, with clear articulate speakers.” Previous delegate
Who should attend
This day would be beneficial to those who work in a clinical or research setting with an advanced understanding of ADHD in children and young people. In particular; consultants, clinical leads, speciality doctors, nurse practitioners, educational psychologists, senior researchers, and those that work with children aﬀected with mental health issues.
The ‘Masterclass Series’
This CPD training day is part of ACAMH’s ‘Masterclass Series’. The ‘Masterclass Series’ delivers advanced, evidence-based training for those working in CYP mental health, to build upon their skills, knowledge and experience. They are interactive sessions, consisting of a series of lectures delivered by world-renowned experts in the field who focus on the latest research, and the implications for best-practice.
Professor of Developmental Psychology and Neuroscience, Department of Child and Adolescent Psychiatry at the IoPPN, Kings College London
Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King’s College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.
His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders. In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.
MD, PhD, Associate Professor at the University of Southampton and Honorary Consultant with Solent NHS Trust
Samuele Cortese, is a child psychiatrist, trained in Italy, France, and in the United States. He is currently an Associate Professor at the University of Southampton and Honorary Consultant with Solent NHS Trust. He is also Adjunct Associate Professor with the New York University (NYU). Dr Cortese’s main research interest are around the epidemiology, neurobiology and treatment of neurodevelopmental disorders, in particular ADHD, as well as on sleep disorders in children and adolescents. He has published more than 120 peer review papers (H index: 39).
Dr Cortese sits on the editorial board of several journals in the field of child mental health, including JCPP, JAACAP, Attention Deficit Hyperactivity Disorders, CNS Drugs, Journal of Child and Adolescent Psychopharmacology and Evidence Based Mental Health. Dr Cortese is a member of the European ADHD Guidelines Group and acts as the ACAMH Branch Liaison Officer.
Amongst our aims is the dissemination of information to bridge the gap between rigorous research and best practice in relation to child and adolescent mental health. One of the ways in which we do this is through our events, and we try to make these as accessible and affordable as is reasonably possible. The events we organise are not profit-making, many are subsidised through our other commercial activities, without which they would not be able to run. As a charity, any surplus that we make is invested back into the business to benefit our Members and the sector. Members get a discounted rate and we hope you consider joining.
NB – The 6 spaces available at Publications/Digital member rate of £74.00 have now all been taken. This event is repeated in September where there are spaces at this rate. Alternatively, Publications and Digital Members can access this event at the Platinum rate.
Platinum member: £147.00
Gold member: £168.00
Silver/Bronze member: £189.00
From a previous ADHD Masterclass our delegates said…
- Overall value – 100% rated good or very good
- Knowledge gained can be used in an impactful way – 100% rated good or very good
- Quality of speakers 100% – rated very good